|  |
| --- |
| **Supplementary Table 1. The criteria for the reimbursement of NUCs by the National Health Insurance Service in the Republic of Korea** |
| **Virological and clinical status** | **Criteria** |
| HBeAg-positive CHB | Serum HBV-DNA ≥ 20,000 IU/mL & Serum AST or ALT ≥ 80 U/mL |
| HBeAg-negative CHB | Serum HBV-DNA ≥ 2,000 IU/mL & Serum AST or ALT ≥ 80 U/mL |
| Compensated cirrhosis | Serum HBV-DNA ≥ 2,000 IU/mL & Serum AST or ALT≥ upper limit of normal |
| **Abbreviations**: NUC, nucleos(t)ide analog; HBeAg, hepatitis B e antigen; CHB, chronic hepatitis B; HBV, hepatitis B virus; AST, aspartate aminotransferase; ALT, alanine aminotransferase |

|  |
| --- |
| **Supplementary table 2. Comparison of baseline characteristics between patients with HCC and those without** |
| **Variables** | **Patients with HCC (N=89)** | **Patients without HCC (N=1721)** | **p-value** |
| Age, years | 56.9 ± 9.3 | 52.1 ± 11.5 | <0.001 |
| Male, no. (%) | 74 (83.1) | 1011 (58.7) | <0.001 |
| Diabetes, no. (%) | 21 (23.6) | 280 (16.3) | 0.070 |
| Hypertension, no. (%) | 41 (46.1) | 362 (21.0) | <0.001 |
| Liver cirrhosis, no. (%) | 43 (48.3) | 496 (28.8) | <0.001 |
| HBeAg positivity, no. (%) | 35 (39.3) | 650 (37.8) | 0.768 |
| AST, IU/mL | 70.6 ± 98.9 | 76.7 ± 133.3 | 0.671 |
| ALT, IU/mL | 66.1 ± 78.2 | 85.3 ±168.9 | 0.286 |
| Total bilirubin, mg/dL | 0.95 ± 0.48 | 1.10 ± 1.92 | 0.445 |
| Albumin, g/dL | 3.96 ± 0.49 | 4.05 ± 0.55 | 0.139 |
| Platelet count, × 103/μL | 137 ± 62 | 181 ± 79 | <0.001 |
| TAF group | 10 (11.2) | 275 (16.0) | 0.231 |
| Data were reported as mean ± standard deviation or no. (%).**Abbreviations**: ETV, entecavir; TAF, tenofovir alafenamie; HBeAg, hepatitis B e antigen; AST, aspartate aminotransferase; ALT, alanine aminotransferase  |